CHAPTER 10: Open Access to the KCNQ Channel: Retigabine and Second Generation M-current Openers
Published:03 Sep 2014
Special Collection: 2014 ebook collection , 2011-2015 industrial and pharmaceutical chemistry subject collectionSeries: Drug Discovery
In 2011, Retigabine (Ezogabine; Valeant Pharmaceuticals/GlaxoSmithKline), an opener of KCNQ (Kv7) potassium channels, was approved for the adjunctive treatment of partial-onset seizures in adult patients. In this chapter, we review the story of retigabine, from identification as a novel anticonvulsant through to clinical testing, and detail the ongoing work to identify a second generation of KCNQ channel openers.